CCM
AERI

Catapult Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Catapult Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,000
Closed -$177K – 245
2015
Q2 		$177K Buy
+10,000
New +$183K 0.03% 213

Other funds holding AERI

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catapult Capital Management's AERI Position: Q3 2015 in Review

Catapult Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2015, closing a stake of 10,000 shares — an estimated $177K sold.

Catapult Capital Management first reported a position in AERI in Q2 2015 and held it in 1 quarter. The position peaked at $177K in Q2 2015. 115 funds tracked by Wall St. Rank hold AERI as of Q3 2015.

  • Catapult Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Catapult Capital Management sold 10,000 Aerie Pharmaceuticals shares in Q3 2015, an estimated $177K.
  • Catapult Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Catapult Capital Management's Aerie Pharmaceuticals position peaked at $177K in Q2 2015.
  • 115 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.